Saso Cemerski, Head of Immunology at Marengo Therapeutics, shared on LinkedIn:
“After 5 amazing years at AZ and building a pipeline that will make a difference for patients, I am excited to share that I have joined Marengo Therapeutics as SVP and Head of Immunology.
Marengo has built an exceptionally innovative immunology platform with the potential to redefine how T-cell engagers activate and redirect the imuune system.
The unique biology of selective Vβ T-cell activation creates an opportunity to overcome many of the limitations of existing T-cell engager approaches. I am excited to join this outstanding team and help translate the TriSTAR platform into a broad pipeline of next-generation therapies for patients.”